Sign in
Taking people in United StatesPhase 2

Tests RTN-001 in adults with high blood pressure not controlled by treatment

Tests RTN-001, or a placebo, in adults with uncontrolled high blood pressure.

Key facts

Who runs it
Retension Pharmaceuticals. Inc.
Where
Alexander City, Asheboro, Bellaire, Birmingham, Bloomfield Hills, Boca Raton, Boston, Charleston, Charlotte, Cincinnati, Dallas, Decatur, Glendale, Indianapolis, Jacksonville, Las Vegas, Lawrenceville, Leesburg, Maitland, Methuen, Monroe, Munster, New Orleans, North Charleston, Orlando, Overland, Pasadena, Peachtree Corners, Plano, Port Orange, San Antonio, San Diego, San Jose, Sugar Land, Tampa, The Bronx, Tucson, Tulsa, Ventura, Vienna, Waterbury, and West Hills, United StatesSee the 42 sites
Trial code
Registry title
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Status
Recruiting
Phase
Phase 2
People taking part
280 people, planned
Started
31 Oct 2025
Expected to end
Jun 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • RTN-001
  • Matching placebo control
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 whose high blood pressure is still not controlled while taking 2-5 blood pressure medicines. It compares RTN-001 with a placebo.

Age
18 to 75 years
Sex
Men and women
Disease stage
Uncontrolled high blood pressure despite a stable regimen of 2-5 blood pressure medicines; mean blood pressure of 135/80 mm Hg or higher; body mass index of 18 to 35 kg/m2.
Earlier treatment
Must be on a stable regimen of 2-5 blood pressure medicines. Cannot currently use or plan to use nitrates, alpha-blockers or other drugs known to affect blood pressure.

Main reasons for not taking part

  • Seated systolic blood pressure above 175 mm Hg and/or diastolic above 110 mm Hg
  • Known secondary hypertension
  • Heart attack, unstable angina or unstable heart rhythm problems within 3 months before screening
  • Liver disease, kidney problems (<45 mL/min/1.73m²) or active cancer
  • Diabetes with glycosylated hemoglobin above 10% or fasting glucose above 250 mg/dl (13.9 mmol/L)

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Male or female patients age 18 to 75 years, inclusive, at the Screening Visit
  • Uncontrolled HTN despite being on a stable regimen of 2-5 antihypertensive medications
  • Mean BP of ≥135/80 mm Hg
  • Body mass index of 18 to 35 kg/m2

Who cannot take part

  • Current or planned use of nitrates and/or alpha-blockers or other drugs known to affect BP during the study period
  • Participants who use PDE5 inhibitors for other indications that cannot or will not refrain from use of PDE5 inhibitors for 7 days before and during their entire period of participation in the study
  • Recent (within 3 months before the Screening Visit [Visit S1]) myocardial infarction; unstable angina leading to hospitalization; uncontrolled, symptomatic atrial fibrillation, or any cardiac arrhythmia that has not been clinically stable for at least 3 months prior to screening. Participants with implantable pacemakers or automatic implantable cardioverter defibrillators may be considered if deemed by the Investigator to be stable for the previous 3 months
  • Any prescription or over-the counter drugs or herbal supplements known to be strong inhibitors of CYP3A4 enzymes
  • History of hypotension, fainting spells, blackouts or autonomic dysfunction, including orthostatic hypotension
  • Known diagnosis of secondary hypertension (e.g. Cushing's Disease or hyperaldosteronism, renal fibrodysplasia, renal artery stenosis, etc., clinically significant aortic stenosis etc.)
  • Liver disease or dysfunction
  • Active infection or major illness
  • Gastrointestinal conditions or procedures (including weight loss surgery [eg, Lap-Band or gastric bypass]) that may affect drug absorption
  • Hematologic or coagulation disorders
  • Active malignancy
  • A known history of temporary or permanent partial or total vision loss
  • A known history of "crowded" optic disc
  • A known history of retinitis pigmentosa, a rare genetic eye disease
  • NHYA class III-IV symptoms of heart failure
  • Unexplained creatine kinase (CK) >3 × ULN at any time before randomization
  • History of diabetes or suspected diabetes with glycosylated hemoglobin > 10% or fasting glucose >250 mg/dl at Screening Visit (S1)
  • Mean seated SBP >175 mm Hg and/or DBP >110 mm Hg
  • Uncontrolled hypothyroidism
  • Renal dysfunction (<45 mL/min/1.73m²) or glomerulonephritis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Alexander City, AlabamaHospital not named in the registryTaking people
  • Asheboro, North CarolinaHospital not named in the registryTaking people
  • Bellaire, TexasHospital not named in the registryTaking people
  • Birmingham, AlabamaHospital not named in the registryTaking people
  • Bloomfield Hills, MichiganHospital not named in the registryTaking people
  • Boca Raton, FloridaHospital not named in the registryTaking people
  • Boston, MassachusettsHospital not named in the registryTaking people
  • Charleston, South CarolinaHospital not named in the registryTaking people
  • Charlotte, North CarolinaHospital not named in the registryTaking people
  • Cincinnati, OhioHospital not named in the registryTaking people
  • Dallas, TexasHospital not named in the registryTaking people
  • Decatur, GeorgiaHospital not named in the registryTaking people
  • Glendale, ArizonaHospital not named in the registryTaking people
  • Indianapolis, IndianaHospital not named in the registryTaking people
  • Jacksonville, FloridaHospital not named in the registryTaking people
  • Las Vegas, NevadaHospital not named in the registryTaking people
  • Lawrenceville, GeorgiaHospital not named in the registryTaking people
  • Leesburg, FloridaHospital not named in the registryTaking people
  • Maitland, FloridaHospital not named in the registryTaking people
  • Methuen, MassachusettsHospital not named in the registryTaking people
  • Monroe, North CarolinaHospital not named in the registryTaking people
  • Munster, IndianaHospital not named in the registryTaking people
  • New Orleans, LouisianaHospital not named in the registryTaking people
  • North Charleston, South CarolinaHospital not named in the registryTaking people
  • Orlando, FloridaHospital not named in the registryTaking people
  • Overland, MissouriHospital not named in the registryTaking people
  • Pasadena, CaliforniaHospital not named in the registryTaking people
  • Peachtree Corners, GeorgiaHospital not named in the registryTaking people
  • Plano, TexasHospital not named in the registryTaking people
  • Port Orange, FloridaHospital not named in the registryTaking people
  • San Antonio, TexasHospital not named in the registryTaking people
  • San Diego, CaliforniaHospital not named in the registryTaking people
  • San Jose, CaliforniaHospital not named in the registryTaking people
  • Sugar Land, TexasHospital not named in the registryTaking people
  • Tampa, FloridaHospital not named in the registryTaking people
  • The Bronx, New YorkHospital not named in the registryTaking people
  • Tucson, ArizonaHospital not named in the registryTaking people
  • Tulsa, OklahomaHospital not named in the registryNot yet recruiting
  • Ventura, CaliforniaHospital not named in the registryTaking people
  • Vienna, VirginiaHospital not named in the registryTaking people
  • Waterbury, ConnecticutHospital not named in the registryTaking people
  • West Hills, CaliforniaHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.

The 4 groups in the trial

  • RTN-001 (15 mg)Treatment being tested

    Treatment: RTN-001

  • RTN-001 (30 mg)Treatment being tested

    Treatment: RTN-001

  • RTN-001 (45 mg)Treatment being tested

    Treatment: RTN-001

  • PlaceboPlacebo, for comparison

    Treatment: Matching placebo control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Plain-language title
Tests RTN-001 in adults with high blood pressure not controlled by treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07142356, who can take part
Record updated
4 November 2026